Title: Esophageal Capsule Endoscopy for Evaluation of Gastroesophageal Reflux Disease Abstract #: P9 Lead Investigator: Disaya Chavalitdhamrong, M.D., Capsule Endoscopy Services Study Group Date/Time: Sunday, October 14, 2007 3:30pm - 7:00pm Location: Exhibit Hall BThis study reports the results of a 312-patient study to determine the use of PillCam ESO as an alternative to esophagogastroduodenoscopy (EGD) to visualize esophageal lesions associated with GERD.
Title: PillCam ESO for Evaluating the Esophagus in the Workplace: Making it Even Easier to Swallow Abstract #: P349 Lead Investigator: Daniel S. Mishkin, M.D., C.M., Instructor of Medicine, Boston University School of Medicine Date/Time: Monday, October 15, 2007 12:15pm - 2:00pm Location: Exhibit Hall BThis study was conducted on the premise that individuals are not being evaluated for acid reflux due to concerns over lost work productivity, fear of traditional methods of evaluation and increased use of over-the-counter medication to suppress symptoms. Physicians conducted a 10-patient pilot study at a major U.S. corporation to determine the feasibility of offering PillCam ESO at an onsite corporate medical facility.
Title: Use of PillCam ESO Endoscopy for Early Detection of Esophageal Injury after Radiofrequency Ablation Therapy for Atrial Fibrillation Abstract #: P14 Lead Investigator: Milan Dodig M.D., Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation Date/Time: Sunday, October 14, 2007 3:30pm - 7:00pm Location: Exhibit Hall BOne new indication being studied is the use of PillCam ESO to detect esophageal injury following radiofrequency ablation for atrial fibrillation. In time, esophageal lesions can lead to development of esophageal fistulas with a high mortality rate. PillCam SB In addition to the PillCam ESO studies being presented, there are numerous studies on PillCam SB, including two 652-patient five-year retrospective studies let by Adnan Muhammad of St. Peter's University Hospital, New Brunswick, New Jersey.
Title: Experience with Wireless Capsule Endoscopy in the Evaluation of Patients with Crohn's Disease Abstract #: P935 Lead Investigator: Adnan Muhammad, MD, Saint Peter's University Hospital Date/Time: Tuesday, October 16, 2007 12:15pm - 2:00pm Location: Exhibit Hall BThis study examines 652 PillCam SB cases from a five-year period to determine the utility of PillCam SB in diagnosing indeterminate colitis and unclassified inflammatory bowel disease.
Title: A Single-Center Experience with 652 Cases of Wireless Capsule Endoscopy over a Period of 5 Years Abstract #: P307 Lead Investigator: Adnan Muhammad, MD, Saint Peter's University Hospital Date/Time: Sunday, October 14, 2007 3:30pm - 7:00pm Location: Exhibit Hall BThis five-year retrospective study of 652 cases determines the frequency of various small bowel indications identified by PillCam SB as well as the diagnostic yield. About Given Imaging Ltd. Given Imaging is redefining gastrointestinal diagnosis by developing, producing and marketing innovative, patient-friendly products for detecting gastrointestinal disorders. The company's technology platform is the PillCam® Platform, featuring the PillCam video capsule, a disposable, miniature video camera contained in a capsule, which is ingested by the patient, a sensor array, data recorder and RAPID® software. Given Imaging has three commercially available capsules: the PillCam SB video capsule to visualize the entire small intestine, which is currently marketed in the United States and in more than 60 other countries; the PillCam ESO video capsule to visualize the esophagus; and the Agile™ patency capsule to determine the free passage of the PillCam capsule in the GI tract. The PillCam COLON video capsule to visualize the colon has been cleared for marketing in the European Union, and multi-center clinical trials are underway in Europe and the U.S. More than 560,000 patients worldwide have benefited from the PillCam capsule endoscopy procedure. Given Imaging's headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel. It has operating subsidiary companies in the United States, Germany, France, Japan and Australia. For more information, visit http://www.givenimaging.com. About Ethicon Endo-Surgery Ethicon Endo-Surgery, Inc., an operating company of Johnson & Johnson, is a global leader in minimally invasive and traditional surgical devices for bariatric surgery and many other areas of surgery. The company develops and markets advanced medical devices for minimally invasive and open surgical procedures. The company focuses on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, plastic surgery, orthopedics, gynecology and surgical oncology. More information on the company can be found at www.ethiconendo.com. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) satisfactory results of clinical trials with PillCam Colon (2) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (3) our success in implementing our sales, marketing and manufacturing plans, (4) protection and validity of patents and other intellectual property rights, (5) the impact of currency exchange rates, (6) the effect of competition by other companies, (7) the outcome of future litigation, including patent litigation with Olympus Corporation, (8) the reimbursement policies for our product from healthcare payors, (9) quarterly variations in operating results, (10) the possibility of armed conflict or civil or military unrest in Israel, and (11) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in the Company's Annual Report on Form 20-F for the year ended December 31, 2006. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company's ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
Contact Information: For further information contact: Fern Lazar David Carey Lazar Partners Ltd. 1-(866) GIVEN-IR